NCT05504252View on ClinicalTrials.gov

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2027

Conditions
Colorectal AdenocarcinomaMucinous AdenocarcinomaSignet Ring Cell Adenocarcinoma
Interventions
DRUG

Nivolumab

"Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks"

DRUG

Oxaliplatin

FLOX, Q2W

Trial Locations (3)

1478

RECRUITING

Akershus University Hospital, Lørenskog

7006

NOT_YET_RECRUITING

St Olavs Hospital, Trondheim

0424

NOT_YET_RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

lead

University Hospital, Akershus

OTHER